Related Experiment Video
Updated: May 8, 2026
Zika Virus Specific Diagnostic Epitope Discovery
Published on: December 12, 2017
Targeting immunogenic proteins of Zika virus for the prediction of immunoinformatics-driven circular mRNA vaccine
Maryam Iftikhar1, Ayesha Khattak1, Nadeem Ahmad2
1Department of Biochemistry, Abdul Wali Khan University Mardan (AWKUM), Mardan, Pakistan.
Abstract:
Zika virus (ZIKV) is an arbovirus with single-stranded RNA that has become a major health concern worldwide, particularly in tropical and subtropical areas where it is transmitted by Aedes aegypti mosquitoes. Infection can leads to severe neurological complications, including microcephaly in infants and Guillain-Barré syndrome in adults. Due to the absence of a licensed vaccine, the current study was conceived to design a novel circular mRNA vaccine, capable of inducing an effective immune response by targeting the ZIKV proteins. Total 26 top-ranked epitopes (IC50 ≤ 100 nM) were prioritized from the conserved regions of ZIKV proteins. A multi-epitope construct was designed by incorporation of prioritized epitopes and β-defensin III adjuvant sequences to enhance immune activation. Molecular docking analysis revealed significant molecular interactions between the designed vaccine molecule and Toll-like receptors (TLRs), predicting an effective immune capability of the model vaccine. Molecular dynamics simulation validated the molecular and structural stability of the vaccine structure under physiological conditions. Immune simulations analysis predicted that the vaccine molecule could boost antibody production and is capable of achieving a global population coverage of 93.22%. Additionally, the circular mRNA vaccine design exhibited stability, with a minimum free energy (MFE) of - 1515.60 kcal/mol and a secondary centroid structure of - 1181.42 kcal/mol, speculating a resilient vaccine framework for potential ZIKV immunity.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s40203-025-00362-0.
Insights
A novel circular mRNA vaccine targeting Zika virus (ZIKV) proteins was designed. This vaccine candidate shows potential for broad population coverage and stability, offering a promising new strategy against ZIKV.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Zika virus (ZIKV) is a significant global health threat, transmitted by Aedes mosquitoes.
- ZIKV infection can cause severe neurological conditions like microcephaly and Guillain-Barré syndrome.
- Currently, no licensed vaccine is available for ZIKV.
Purpose of the Study:
- To design a novel circular mRNA vaccine targeting ZIKV proteins.
- To evaluate the vaccine's potential for inducing an effective immune response.
- To assess the vaccine's stability and population coverage.
Main Methods:
- Prioritization of 26 top-ranked epitopes from conserved ZIKV protein regions.
- Design of a multi-epitope construct with a β-defensin III adjuvant.
- Molecular docking and dynamics simulations to assess interactions and stability.
- Immune simulations to predict antibody production and population coverage.
Main Results:
- The designed vaccine construct demonstrated significant interactions with Toll-like receptors (TLRs).
- Molecular dynamics simulations confirmed the vaccine's structural stability under physiological conditions.
- Immune simulations predicted a 93.22% global population coverage and enhanced antibody production.
- The circular mRNA vaccine exhibited high stability with a minimum free energy of -1515.60 kcal/mol.
Conclusions:
- The novel circular mRNA vaccine design shows promise for ZIKV immunity.
- The vaccine's stability and predicted high population coverage make it a resilient candidate.
- Further development could lead to a viable vaccine against Zika virus.
